📰 Morphosys Agview News
Morphosys Agview News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Morphosys Agview. Real-time updates on events, politics, business and more.
April 27, 2023
Conference Call AlertMUNICH, GERMANY / ACCESSWIRE / April 27, 2023 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) will publish its results for the first quarter 2023 on May 3, 2023 at 10:00 pm CEST (09:00 pm BST
March 2, 2023
MUNICH, GERMANY / ACCESSWIRE / March 2, 2023 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that the company will stop work and operations on its pre-clinical research programs to optimize its cost
January 5, 2023
Preliminary 2022 Monjuvi U.S. net product sales of US$ 89.4 million ( € 84.9 million)Anticipated 2023 Monjuvi U.S. net product sales in the range of US$ 80 to 95 millionPreliminary unaudited financial
November 28, 2022
PLANEGG / MUNICH, GERMANY / ACCESSWIRE / November 28, 2022 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) publishes its financial calendar dates for the year 2023:Publication of Interim Statement / ReportConference
October 27, 2022
PLANEGG / MUNICH, GERMANY / ACCESSWIRE / October 27, 2022 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) announced today that its licensing partner, GSK plc (GSK), provided an update on the ContRAst phase III program
October 27, 2022
The findings, including encouraging preliminary efficacy data in various tumor types, were presented during the 34th EORTC-NCI-AACR SymposiumPLANEGG/MUNICH, GERMANY / ACCESSWIRE / October 27, 2022 / MorphoSys
October 21, 2022
MorphoSys Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022Preliminary Q3 2022 Monjuvi U.S. net product sales of US$ 22.2 million (€ 21.9 million)Anticipated full year